Vertex Pharmaceuticals Inc
VRTX:NASDAQ
| Last | Change / % Change | Dividend Yield | Volume |
| 39.42 | 0.8700 2.26% | 0.00% | 3,006,503 |
Market data is delayed by at least 20 minutes.
Exclusive Features
When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes.
For full analysis details, Log In with Scottrade or you can:
Latest News Headlines for Vertex Pharmaceuticals Inc
Uptrend Spotted in Shares of Vertex Pharmaceuticals (VRTX)
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on December 20, 2010 at $35.52. In approximately 4 weeks, Vertex Pharmaceuticals has returned 11% as of today's recent price of $39.42.
Shares of MannKind Rank the Highest in terms of Relative Performance in the Biotechnology Industry (MNKD, VRTX, AMLN, THRX, NPSP)
Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.
Vertex Pharmaceuticals (VRTX) Showing Bullish Technicals But Could Fall Through $35.72 Support
View more recent headlinesVertex Pharmaceuticals Inc (NASDAQ: VRTX) closed Tuesday's trading session at $36.79. In the past year, the stock has hit a 52-week low of $31.25 and 52-week high of $43.94. Vertex Pharmaceuticals stock has been showing support around $35.72 and resistance in the $38.38 range. Technical indicators for the stock are Bullish and S&P; gives VRTX a very positive 5 STARS (out of 5) strong buy rating. For a hedged play on this stock, look at the Apr '11 $36.00 covered call for a net debit in the $33.59 area. That is also the break-even stock price for this trade. This covered call has a duration of 94 days, provides 8.70% downside protection and an assigned return rate of 7.17% for an annualized return rate of 27.86% (for comparison purposes only). A lower-cost hedged play for this stock would use a longer term call option in place of the covered call stock purchase. To use this strategy look at going long the VRTX Jan '12 $25.00 call and selling the Apr '11 $36.00 call for a total debit of $10.45. The trade has a lifespan of 94 days and would provide 3.64% downside protection and an assigned return rate of 5.26% for an annualized return rate of 20% (for comparison purposes only). Vertex Pharmaceuticals does not pay dividends at this time.
Company Background
Vertex Pharmaceuticals Incorporated (Vertex) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the Company's lead drug candidate, is an oral hepatitis C protease inhibitor and a new class of antiviral treatments in clinical development that target hepatitis C virus (HCV), infection. Telaprevir is being evaluated in a registration program focused on treatment-naïve and treatment-failure patients with genotype 1 HCV infection. VX-770, the lead drug candidate in its cystic fibrosis (CF), program is being evaluated in a registration program that focuses on patients with CF who have the G551D mutation in the gene responsible for CF. Vertex is conducting a number of Phase IIa clinical trials of its earlier-stage drug candidates. On March 12, 2009, Vertex acquired ViroChem Pharma Inc. (ViroChem).
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 38.56 | Previous Close 38.55 |
Day High 39.42 | Day Low 38.32 |
52wk High/Date 43.94 / 3/16/2010 | 52wk Low/Date 31.25 / 7/1/2010 |
Beta 0.55 | Market Capitalization 8B |
Shares Outstanding 203M | Volatility Avg 29.79 |
Avg Vol(10 day) 2M | P/E Ratio NM |
EPS (TTM) -4 | Annualized Rate -- / -- |
Yield 0.00% | Dividend Announcement -- |
Ex-Date -- | Date of Record -- |
Payable 0.00 - -- | Payable Date -- |
Last Trade as of 1/14/2011 4:00 PM ET | |
Exclusive Content
When you open an account with Scottrade, you will get premium content on the News & Content page, including:
- Standard & Poor's News and Commentary
- Dow Jones News
- Briefing News and Commentary
- Market Edge On the Edge Commentary
For full analysis details, Log In with Scottrade or you can:
VRTX Vertex Pharmaceuticals Inc vs. Peers
| Peers | |
VRTX Vertex Pharmaceuticals Inc | 12.53% |
| MRK Merck & Co., Inc. | -5.02% |
| PFE Pfizer Inc. | 4.74% |
| AMGN Amgen, Inc. | 2.91% |
| JNJ Johnson & Johnson | 1.13% |
VRTX Vertex Pharmaceuticals Inc | 0.00% |
| MRK Merck & Co., Inc. | 4.44% |
| PFE Pfizer Inc. | 4.36% |
| AMGN Amgen, Inc. | -- |
| JNJ Johnson & Johnson | 3.45% |
VRTX Vertex Pharmaceuticals Inc | 2.26% |
| MRK Merck & Co., Inc. | -1.33% |
| PFE Pfizer Inc. | 0.66% |
| AMGN Amgen, Inc. | 0.32% |
| JNJ Johnson & Johnson | -0.57% |